SC Dermatology U-V
Scientific area: SC Dermatology U- Department of Medical Sciences
Director: Prof. Pietro Quaglino
Researchers: Prof. Simone Ribero
- Prof. Pietro Quaglino -Director
- Prof. Simone Ribero - Researchers
- Sara Marchisio - PhD
- Pietro Grignani, Silvia Scaglia, Erica Baima, Gennaro Passaro, Ofelia LabriolaValentina Gala, Camilla Brondino, Luca Cangialosi, Giuseppe Ferrua, Lorenzo Marega, Ilaria Gazaneo , Simone Tavassoli - Thesis students
- Renata Ponti -Head group Clinical Trials group, PhD
- Director SC Dermatologia U -1° piano P.O. San Lazzaro – Via Cherasco 23-10129 Torino email pietro.quaglino@unito.it
- Immunopatologia Cutanea -1° piano san Lazzaro – via cherasco 23-10129 Torino; Tel 011-6335858-6899 Fax 0116335808, e-mail dermo_trials_molinette@unito.it
- Trials clinici Farmacologici di fase II, III e IV Sponsorizzati e No profit
- Cutaneous lymphoma: clinical, histological and immunological features of lymphoproliferative skin disorders; CD26 expression in the skin and blood of patients with cutaneous T-cell lymphoma; cytokine levels; therapeutical innovative approaches such as extracorporeal photochemotherapy, monoclonal antibodies, target therapies, new chemotherapic drugs.
- Melanoma: immunology; risk factors; clinical and histological prognostic factors; role of the sentinel lymph node biopsy and associated prognostic parameters;; new therapeutic approaches (electrochemotherapy, ipilimumab, target therapies, anti-PD1); molecular markers specifically mRNA for tyrosinase.
- Immune-mediated dermatoses: clinical features of specific entities in multicentric series; clinico-pathologic features, immunological patterns of activation, apoptosis in the spectrum erythema multiforme/Stevens-Johnson syndrome/Toxic epidermal necrolysis; Adhesion molecules, immune activation pattern and skin homing in inflammatory dermatoses and erythroderma; regulatory T-cell expression and monitoring in the peripheral blood of patients with different dermatological diseases, such as psorias, atopic dermatitis, scleroderma, bullous pemphigoid, graft-versus-Host-disease, correlation with the extent of cutaneous involvement, treatment response and disease course.
- Roccuzzo G, Moirano G, Fava P, Maule M, Ribero S, Quaglino P. Obesity and immune-checkpoint inhibitors in advanced melanoma: A meta-analysis of survival outcomes from clinical studies. Semin Cancer Biol. 2023 Mar 4;91:27-34. doi:10.1016/j.semcancer.2023.02.010. Epub ahead of print. PMID: 36871633.
- Gasparini G, Cozzani E, Di Zenzo G, Salemme A, Dematté E, Vassallo C, Marzano AV, Genovese G, Caproni M, Antiga E, Quaglino P, Parodi A; Cutaneous Immunology Group of SIDeMaST. Anti-laminin 332 antibody detection using biochip immunofluorescence microscopy in a real-life cohort of Italian patients with mucous membrane pemphigoid. Eur J Dermatol. 2022 Nov 1;32(6):756-761. English. doi: 10.1684/ejd.2021.4104. PMID: 36856373
- Ascierto PA, Cioli E, Chiarion-Sileni V, Quaglino P, Spagnolo F, Guidoboni M, Del Vecchio M, Peris K, Queirolo P, Fioretto L, Caracò C, Paone M, Sorrentino A,Capone M, Giannarelli D, Ferrara G, Massi D, Trojaniello C. Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study. Front Oncol. 2023 Feb 9;13:1107307. doi: 10.3389/fonc.2023.1107307. PMID: 36845751; PMCID: PMC9949553
- Avallone G, Maronese CA, Murgia G, Carrera CG, Mastorino L, Roccuzzo G, Dapavo P, Alberti-Violetti S, Quaglino P, Ribero S, Marzano AV. Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study. J Clin Med. 2023 Feb 19;12(4):1662. doi: 10.3390/jcm12041662. PMID: 36836196; PMCID: PMC9962195.
- Quaglino P, Novelli M, Fava P, Ortolan E, Astrua C, Tonella L, Tomasini CF, Senetta R, Ribero S, Ponti R, Fierro MT, Funaro A. CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study. Dis Markers. 2022 Feb 24;2022:3424413. doi: 10.1155/2022/3424413. PMID: 35251370; PMCID: PMC8896155
- Cutaneous Lymphoma International Consortium (CLIC) project (3,200 dollari) (2014)- Stanford University San Francisco. Colalborator/consultant
- European Academy of Dermato Venereology Proposal n°2014-023, A Multicentre International Prospective Observational Study for the Identification of Prognostic Factors in Patients with Mycosis Fungoides/Sézary Syndrome: Proposal for a Multicentre Data Integration Study for the Development of a Prognostic Index (2014) (Total funding 100,000 euro). role : Participant
- Cutaneous Lymphoma Foundation Catalyst Research Grant 2021: 50,000 euro Responsabile
- PRIN 2021: A multiparametric approach based on circulating biomarkers to monitor response and immune-related adverse reactions to immunotherapy of cancer. Contributo totale MIUR 726.253 Responsabile di Unità di Ricerca
- “Precision Medicine in neoplasia: omics and big data” inoltre partecipato come Principal Investigator per l’Area Oncologica –Progetto Strategico di Eccellenza Dipartimentale, DSM, UNITO Project n. D15D18000410001 Dipartimento di Scienze Mediche, UNITO, nell’ambito del programma TESEO
- Video YouTubePolo Medicina Torino · 2022
- Video YouTubeAccademia di Medicina di Torino 2022
- Video YouTube PharmaStarTV 2022
- Video Polo Medicina Torino @polomedicinatorino8421- Dermatologia I, II, III